Treatment of Depression in Parkinson’s Disease

Richard, Irene Hegeman

doi:10.1007/978-3-319-97897-0_26

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, behavioral symptoms, dopamine, dopaminergic neurons, nigrostriatal lesion underlying cause (Bohnen et al, 2015;Grimbergen et al, 2009;Lou et al, 2015;Olivola et al, 2014). Varying between epidemiological studies, occurrence of depression ranges from 35% to 58% and anxiety, panic attacks, and other phobias appear in 40% of PD cases (Pontone et al, 2011;Richard, 2005). Attempts to detect depression and psychosis in MPTP mouse models have met with little success (Okano et al, 2019.…”

Section: Introductionmentioning

confidence: 99%

“…To date, the neuropathological bases of NMS are not fully understood, and in addition to the reduced DA content, altered levels of serotonin (5‐HT), norepinephrine and acetylcholine are likely to be the underlying cause (Bohnen et al, 2015; Grimbergen et al, 2009; Lou et al, 2015; Olivola et al, 2014). Varying between epidemiological studies, occurrence of depression ranges from 35% to 58% and anxiety, panic attacks, and other phobias appear in 40% of PD cases (Pontone et al, 2011; Richard, 2005). Attempts to detect depression and psychosis in MPTP mouse models have met with little success (Okano et al, 2019, Li et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neurochemical, histological, and behavioral profiling of the acute, sub‐acute, and chronic MPTP mouse model of Parkinsonʼs disease

Santoro

Fadda

Klephan

et al. 2022

Journal of Neurochemistry

View full text Add to dashboard Cite

Parkinson's disease (PD) is a heterogeneous multi-systemic disorder unique to humans characterized by motor and non-motor symptoms. Preclinical experimental models of PD present limitations and inconsistent neurochemical, histological, and behavioral readouts. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD is the most common in vivo screening platform for novel drug therapies; nonetheless, behavioral endpoints yielded amongst laboratories are often discordant and inconclusive. In this study, we characterized neurochemically, histologically, and behaviorally three different MPTP mouse models of PD to identify translational traits reminiscent of PD symptomatology. MPTP was intraperitoneally (i.p.) administered in three different regimens: (i) acute-four injections of 20 mg/kg of MPTP every 2 h; (ii) sub-acute-one daily injection of 30 mg/kg of MPTP for 5 consecutive days; and (iii) chronic-one daily injection of 4 mg/kg of MPTP for 28 consecutive days. A series of behavioral tests were conducted to assess motor and non-motor behavioral changes including anxiety, endurance, gait, motor deficits, cognitive impairment, circadian rhythm and food consumption. Impairments in balance and gait were confirmed in the chronic and acute models, respectively, with the latter showing significant correlation with lesion size. The subacute model, by contrast, presented with generalized hyperactivity. Both, motor and non-motor changes were identified in the acute and sub-acute regime where habituation to a novel environment was significantly reduced. Moreover, we report increased water and food intake across all three models. Overall, the acute model displayed the most severe lesion size, while across the three models striatal dopamine content (DA) did not correlate with the behavioral performance. The present study demonstrates that detection of behavioral changes following MPTP exposure is challenging and does not correlate with the dopaminergic lesion extent.

show abstract